These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 12949685)

  • 1. Potentiated antibodies to tumor necrosis factor-alpha in the therapy of patients with rheumatoid arthritis.
    Kozlovskaya LV; Mukhin NA; Rameev VV; Sarkisova IA; Epstein OI
    Bull Exp Biol Med; 2003 Jan; 135 Suppl 7():152-4. PubMed ID: 12949685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficiency of potentiated antibodies to tumor necrosis factor-alpha (Artrofoon) in the therapy of patients with rheumatoid arthritis.
    Petrov VI; Babaeva AR; Cherevkova EV; Epstein OI; Sergeeva SA
    Bull Exp Biol Med; 2003 Jan; 135 Suppl 7():155-8. PubMed ID: 12949686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of combination of anticytokine preparations anaferon and artrofoon on immune inflammation in rheumatoid arthritis.
    Petrov VI; Babaeva AR; Solodenkova KS; Cherevkova EV; Zabolotneva YA; Kachanova MV; Sergeeva SA
    Bull Exp Biol Med; 2009 Sep; 148(3):489-92. PubMed ID: 20396720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficiency and safety of long-term artrofoon treatment in rheumatoid arthritis.
    Petrov VI; Babaeva AR; Cherevkova EV; Kachanova MV; Zabolotneva YA; Tarasov SA; Dugina YL; Sergeeva SA
    Bull Exp Biol Med; 2009 Sep; 148(3):486-8. PubMed ID: 20396719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, open-label, comparative, 6-month trial of oral ultra-low doses of antibodies to tumor necrosis factor-alpha and diclofenac in rheumatoid arthritis.
    Dugina JL; Petrov VI; Babayeva AR; Martyushev-Poklad AV; Tcherevkova EV; Epstein OI; Sergeeva SA
    Int J Tissue React; 2005; 27(1):15-21. PubMed ID: 15847101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficiency and tolerability of artrofoon in patients with rheumatoid arthritis associated with osteopenic syndrome.
    Peshekhonova LK; Chernov YN; Barsukova NA; Peshekhonov DV
    Bull Exp Biol Med; 2009 Sep; 148(3):468-9. PubMed ID: 20396714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental and clinical study of the effect of artrofoon on proinflammatory cytokine production.
    Kachanova MV; Sherstoboyev EY; Babayeva AR; Tcherevkova EV; Dugina JL; Kislitsyna OS; Epstein OI; Sergeeva SA
    Bull Exp Biol Med; 2008 Jan; 145(1):58-61. PubMed ID: 19024003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Canadian variation by province in rheumatoid arthritis initiating anti-tumor necrosis factor therapy: results from the optimization of adalimumab trial.
    Pease C; Pope JE; Thorne C; Haraoui BP; Truong D; Bombardier C; Widdifield J; Psaradellis E; Sampalis JS; Bonner A
    J Rheumatol; 2010 Dec; 37(12):2469-74. PubMed ID: 20843910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination DMARD therapy for rheumatoid arthritis.
    Kremer JM
    Manag Care; 2001 Jul; 10(7 Suppl):10-4. PubMed ID: 11729428
    [No Abstract]   [Full Text] [Related]  

  • 11. The future role of anti-tumour necrosis factor (TNF) products in the treatment of rheumatoid arthritis.
    Camussi G; Lupia E
    Drugs; 1998 May; 55(5):613-20. PubMed ID: 9585859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
    Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y
    J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
    [No Abstract]   [Full Text] [Related]  

  • 13. [Pharmacotherapy of rheumatoid arthritis in the era of genetically engineered biological preparations].
    Nasonov EL
    Ter Arkh; 2007; 79(5):5-8. PubMed ID: 17672066
    [No Abstract]   [Full Text] [Related]  

  • 14. Anticytokine therapy--a new era in the treatment of rheumatoid arthritis?
    O'Dell JR
    N Engl J Med; 1999 Jan; 340(4):310-2. PubMed ID: 9920958
    [No Abstract]   [Full Text] [Related]  

  • 15. Demonstration of response in rheumatoid arthritis patients who are nonresponders according to the American College of Rheumatology 20% criteria: the paradox of beneficial treatment effects in nonresponders in the ATTRACT trial. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy.
    Boers M;
    Arthritis Rheum; 2001 Nov; 44(11):2703-4. PubMed ID: 11710727
    [No Abstract]   [Full Text] [Related]  

  • 16. Synovial synoviolin in relation to response to TNF blockade in patients with rheumatoid arthritis and psoriatic arthritis.
    Klaasen R; Wijbrandts CA; van Kuijk AW; Pots D; Gerlag DM; Tak PP
    Ann Rheum Dis; 2012 Jul; 71(7):1260-1. PubMed ID: 22345123
    [No Abstract]   [Full Text] [Related]  

  • 17. Development of type 1 diabetes mellitus in a patient with rheumatoid arthritis receiving anti-tumor necrosis factor alpha.
    Richez C; Blanco P; Gin H; Schaeverbeke T
    Clin Exp Rheumatol; 2006; 24(5):607. PubMed ID: 17181936
    [No Abstract]   [Full Text] [Related]  

  • 18. Anti-tumor necrosis factor-alpha therapy provokes latent leishmaniasis in a patient with rheumatoid arthritis.
    Franklin G; Greenspan J; Chen S
    Ann Clin Lab Sci; 2009; 39(2):192-5. PubMed ID: 19429808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of artrofoon in the treatment of ankylosing spondyloarthritis.
    Kudryavtseva IV; Ukolova LA; Chizhov NN; Braginskaya NM; Istranen IA; Kozhevnikov OP
    Bull Exp Biol Med; 2009 Sep; 148(3):474-7. PubMed ID: 20396716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Biological agents for therapy of rheumatoid arthritis--overview].
    Takeuchi T
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():513-6. PubMed ID: 15799409
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.